Dr. David Goeddel is former head of Genentech’s microbiology department, CU Biochemistry alum Class of ‘77, and the scientist behind the first commercially viable insulin biosynthesis pipeline in human history. Today, Dr. Goeddel continues to drive innovation as a managing partner of The Column Group , a venture capitalist firm...